Phase II Trial of Irinotecan Plus Paclitaxel in Patients With Advanced Nonsmall Cell Lung Cancer
- Determine the antitumor activity and toxicities of irinotecan and paclitaxel in
patients with advanced non-small cell lung cancer.
OUTLINE: Patients receive paclitaxel IV over 1 hour followed immediately by irinotecan IV
over 30 minutes. Treatment continues weekly for 2 weeks followed by one week of rest.
Courses are repeated every 3 weeks in the absence of disease progression or unacceptable
Patients are followed every 3 months for 1 year, then every 6 months thereafter.
PROJECTED ACCRUAL: A total of 11-22 patients will be accrued for this study over 12 months.
Primary Purpose: Treatment
John R. Murren, MD
United States: Federal Government
|Yale Comprehensive Cancer Center||New Haven, Connecticut 06520-8028|
|Northwestern Connecticut Oncology-Hematology Associates - Torrington||Torrington, Connecticut 06790|